Fuchs DystrophyNCT00346138
A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema
A study testing Corneal transplantation in people with Fuchs Dystrophy and Corneal Edema, run by Mayo Clinic at 1 site in United States.
Trial summary
The objectives of this study are to compare the visual and refractive outcomes of deep lamellar endothelial keratoplasty (DLEK) with penetrating keratoplasty as treatment for certain cases of corneal edema due to endothelial decompensation. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Fuchs Dystrophy, Corneal Edema
- What is being tested?
- Corneal transplantation
- Type of treatment
- Surgery or procedure
- How many people
- 29 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2005to Jun 2009
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
- Corneal edema due to endothelial dysfunction
- Aphakia, pseudophakia, or cataract requiring extraction
- Visual acuity in a) study eye; best spectacle-corrected entrance acuity 20/40 or worse. b)contralateral eye; best spectacle-corrected entrance acuity equal to or better than the study eye and 20/200 or better.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Deep Lamellar Endothelial Keratoplasty as Surgical Treatment for Corneal Endothelial Decompensation
The objectives of this study are to compare the visual and refractive outcomes of deep lamellar endothelial keratoplasty (DLEK) with penetrating keratoplasty as treatment for certain cases of corneal edema due to endothelial decompensation. Additionally, data will be collected to compare corneal shape, corneal thickness, endothelial cell density, keratocyte density, corneal sensitivity, light scatter, and subjective visual function between the two procedures.
Read the detailed description
This will be a randomized prospective study. We will enroll patients using the following inclusion and exclusion criteria, based upon the surgeon?s initial complete ophthalmic examination, which includes refraction, keratometry, slit lamp examination, intraocular pressure and corneal thickness measurement, and dilated fundus examination.
Inclusion criteria:
- Both males and females are eligible 2) Patient age 21 years or older 3) Corneal edema due to endothelial dysfunction 4) Aphakia, pseudophakia, or cataract requiring extraction 5) Visual acuity as measured in standardized fashion (ETDRS chart and appropriate illumination)
- Study eye; best spectacle-corrected entrance acuity 20/40 or worse
- Contralateral eye; best spectacle-corrected entrance acuity equal to or better than the study eye and 20/200 or better. Exclusion criteria:
- Central stromal corneal scars 2) Presence of a filtering bleb 3) History of Herpes simplex or Herpes zoster keratitis 4) Uncontrolled glaucoma 5) Pregnancy. Serum pregnancy testing will be performed within 7 days prior to surgery for women of child-bearing potential In the 2-year period, January 2001 to January 2003, 67 PK?s were performed at Mayo Clinic for endothelial dysfunction (e.g., Fuch?s dystrophy or pseudophakic corneal edema) in patients who met the entry criteria for this protocol. During the 2-year enrollment period of this study, we anticipate that up to 50 patients will be enrolled. Appropriate counseling will be done, including a discussion of the potential benefits and risks of the procedures. IRB-approved consent forms will be signed. Enrolled patients will return on a different day (often the day before surgery or the morning of surgery to be performed in the afternoon) for the preoperative Keratogram. Randomization and assignment of the patient to DLEK or PK will occur after the preoperative Keratogram and after the surgeon has accepted a donor cornea from the eye bank for the procedure. Keratogram The Keratogram consists of a series of tests administered both pre- and post-operatively by trained research personnel who are masked to the patients? particular randomizations. Keratograms will be performed preoperatively and at 1 month (3-6 weeks), 3 months (2-4 months), 6 months (5-7 months), and 1, 2, and 3 years (\3 months) postoperatively. The following measurement procedures, to be conducted only on the operated eye, are included in each Keratogram. The equipment to be used is included in parentheses:
- Contrast sensitivity with best refraction (Ginsburg contrast sensitivity tester) 2. Straylight meter measurement (Van den Berg straylight meter) 3. Corneal topography map (TMS-2) 4. Corneal profile (Orbscan) 5. Noncontact endothelial photography (Konan Robo) 6. Scatterometry (Mayo scatterometer) 7. Corneal esthesiometry (Belmonte esthesiometer) 8. Confocal microscopy (Tandem Scanning or Confoscan 3 confocal microscope) 9. Quality of visual function questionnaire (NEI-VFQ). This will not be done at the 1week, one month, or 3 month visit. Eligibility of Fellow Eyes Fellow eyes in bilateral cases will be eligible to enter the study 4 months or more after the first procedure if these eyes now meet the eligibility criteria (i.e., if the fellow eye now has worse vision than the operated study eye). These eyes will be randomized separately and follow the same protocol, with the exception that the patient may override the randomization if he or she prefers to have one or the other of the 2 procedures. For data analysis, fellow eyes will be considered a separate group. Adverse Occurrences For DLEK, adverse occurrences at the time of surgery (such as premature entry into the anterior chamber during recipient lamellar dissection) will require conversion to a standard PK and the patient will be exited from the study. Adverse postoperative occurrences in either surgical group (such as a dislocated disc, uncontrolled rejection, primary graft failure, infection or other adverse events) will be managed by the surgeon according to standard practices. These patients will remain in the study and will have identical follow-up. SURGICAL METHODS
- DLEK Anesthesia: Anesthesia options will include monitored, attended, local anesthesia or general orotracheal anesthesia, depending on the particular patient?s desire and comorbid conditions. For local anesthesia a standard retrobulbar and facial nerve block as done for standard PK will be utilized. Preparation of recipient:
- In the preoperative area, pilocarpine 1%, one drop to operated eye is instilled every five minutes for 3 doses in order to constrict the pupil.
- After anesthesia is attained and the eye is prepared and draped, the lid speculum and operating microscope with video recording of each case is brought into position.
- Rectus bridle sutures for positioning of the globe are placed as necessary.
- A limbal peritomy is performed and the conjunctiva is recessed from the 9:30 to 2:30 o'clock superior limbus.
- A limbal incision of the sclera, 1.0 mm peripheral to the limbus and parallel to the limbus, is made with a guarded diamond knife set to 0.35 mm depth. The length of the incision is 9.0 mm or 4.5mm, measured with calipers.
- Deep lamellar dissection of the cornea utilizing a crescent blade is performed followed by a stromal dissector spatula.
- Paracentesis and Healon injection to maintain the anterior chamber.
- Placement of intra-lamellar trephine with trephination of the recipient posterior stromal disc. If a 4.5mm incision was made, then the trephine is used to make an indentation on the corneal surface and the posterior lamellar disc is cut with scissors.
- Entry into anterior chamber with a diamond blade at 12 o'clock in the trephination.
- Excision of recipient posterior stromal disc and endothelium with corneal scissors and removal of disc from the eye.
- Caliper measurement of the diameter of the excised tissue is recorded.
- Wound closure and standard phacoemulsification and IOL implantation through a separate incision in patients requiring cataract removal.
- Healon is evacuated completely from the anterior chamber with an I/A unit. (eg: Simcoe Needle).
- The cornea is covered with a moistened gauze disc. Preparation of donor tissue
- Donor corneo-scleral tissue is removed from the storage media, endothelium is coated with healon, and the tissue is secured in the Moria artificial anterior chamber.
- A deep lamellar dissection pocket is formed in the donor with a crescent blade followed by a stromal dissector spatula.
- The donor tissue is placed (endothelial side up) onto the trephination block and the same size trephine (same size as recipient disc tissue diameter) is used to trephine the donor disc.
- The donor disc is separated from the corneo-scleral donor tissue and placed endothelial side down or folded in half (if a 4.5mm incision was made) onto a healon coated transfer spatula. Transfer of donor to recipient
- Air is injected into the anterior chamber. 2) The donor tissue disc is placed into the anterior chamber through the lamellar incision.
- The spatula is removed from the eye by sliding out from under the Healon coating.
- The disc position is finely manipulated with a needle or hook as needed, taking care to minimize endothelial touch.
- The limbal wound is sutured with interrupted 10-0 nylon sutures. 6) The anterior chamber air bubble is replaced 50% with balanced salt solution. 7) A Seidel test is performed. If positive, additional limbal sutures are placed.
- The conjunctiva is closed with cautery or sutures. 9) Subconjunctival dexamethasone, 2 mg or Solu-Medrol, 30 mg and cefazolin, 25 mg or gentamicin, 20 mg, are injected in the inferior fornix. The eye is bandaged with a gauze patch and a Fox shield.
- The patient is instructed to spend the next two postoperative hours in a supine position.
- Routine postoperative orders for corneal transplantation are given upon discharge from the hospital that day.
- PK The surgical method for patients randomized to penetrating keratoplasty will be the standard procedure currently practiced by the participating surgeons. POSTOPERATIVE CARE The patient will be seen the day after the surgery. Postoperative medications will include topical antibiotic of the surgeon?s choice, twice daily for one to two weeks and prednisolone acetate 1%, four times daily. The steroid drop will be tapered by one drop daily each month. Alterations to the steroid taper and other medical treatment will be made based upon individual patient conditions and response. Patient activity restrictions and eye protection measures will follow the usual PK recommendations by the individual surgeon. All patients will be seen at the following intervals: preoperatively and at 1 week (5-14 days), 1 month (3-6 weeks), 3 months (4-6 months), 6 months (5-7 months), and 1, 2, and 3 years (\3 months) postoperatively. Keratograms will be performed at each visit, except one day and one week postoperatively. Confocal microscopy will be done as part of each keratogram and also at the one week postoperative visit. Additional clinic visits may be requested by the surgeon as needed for proper medical management. Corneal suture removal in penetrating grafts or limbal suture removal in DLEK will be dictated by patient healing and at the surgeon?s discretion. DATA COLLECTION AND STATISTICAL ANALYSIS Data collection will be performed with the instruments and schedule delineated above in the Methods section. The following outcome measures will be calculated from the data. These will be compared between the 2 groups (DLEK and PK) at each postoperative time by using t-tests or rank sum tests with Bonferroni corrections. Primary Outcome Measures
- Visual acuity with best refractive correction
- Refractive astigmatism
- Keratometric astigmatism
- Topographic astigmatism ("Simulated Keratometry" function of the TMS-1 mapping) Secondary Outcome Measures <!-- -->
- Corneal backscattered light
- Ocular forward-scattered light
- Contrast sensitivity
- Posterior corneal curvature
- Corneal sensitivity
- Corneal subbasal nerve density
- Keratocyte density
- Endothelial cell density
- Quality of visual function (NEI-VFQ) Statistical Power We have recently published variance data on keratometric astigmatism and endothelial cell density after PK. The keratometric astigmatism17 after removal of all sutures was 4.6 \ 2.7 D (mean\SD) and the endothelial cell density18 2 months postoperatively was 2606 \ 446 cells/mm2. To detect (\=0.05) a difference of 2.5 D in keratometric astigmatism with 80% certainty (\=0.2) would require 20 subjects in each group, and to detect a difference of 400 cells/mm2 in endothelial cell density would require 20 subjects in each group. We expect to have 25 patients in each group, giving the study adequate power. For an additional use of the data, primary outcome data on the patients randomized to DLEK from our center will be pooled with data from other participating centers in the Endothelial Keratoplasty Group organized by Mark Terry, M.D., Portland, OR, who will coordinate data collection and statistical analysis. Pooled data will be used to calculate mean postoperative visual acuity, refractive outcomes and frequency of favorable outcome. These data will be compared with published data on PK.
- Conditions
- Fuchs Dystrophy, Corneal Edema
- Being tested
- Corneal transplantation
- Medical subject headings
- Fuchs' Endothelial Dystrophy, Corneal Edema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Corneal transplantationProcedure or surgery
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual acuity.
Secondary outcomes (5)
Astigmatism
contrast sensitivity
corneal haze
endothelial cell density
corneal thickness
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2006 (estimated)
- Study startJun 2005
- Primary completionJun 2009
- Study completionJun 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Fuchs DystrophyStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 29 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00346138
- Sponsor's protocol ID
- 1000-03
- Status last verified
- Jan 2010
- First submitted
- 27 Jun 2006
- Last updated
- 15 Jan 2010
- Results posted
- No
Publications
Trousdale ER, Hodge DO, Baratz KH, Maguire LJ, Bourne WM, Patel SV. Vision-related quality of life before and after keratoplasty for Fuchs' endothelial dystrophy. Ophthalmology. 2014 Nov;121(11):2147-52. doi: 10.1016/j.ophtha.2014.04.046. Epub 2014 Jul 9.
PubMed 25015214Ahuja Y, Baratz KH, McLaren JW, Bourne WM, Patel SV. Decreased corneal sensitivity and abnormal corneal nerves in Fuchs endothelial dystrophy. Cornea. 2012 Nov;31(11):1257-63. doi: 10.1097/ICO.0b013e31823f7888.
PubMed 22357383McLaren JW, Patel SV, Bourne WM, Baratz KH. Corneal wavefront errors 24 months after deep lamellar endothelial keratoplasty and penetrating keratoplasty. Am J Ophthalmol. 2009 Jun;147(6):959-65, 965.e1-2. doi: 10.1016/j.ajo.2008.12.039. Epub 2009 Mar 19.
PubMed 19298950Patel SV, McLaren JW, Hodge DO, Baratz KH. Scattered light and visual function in a randomized trial of deep lamellar endothelial keratoplasty and penetrating keratoplasty. Am J Ophthalmol. 2008 Jan;145(1):97-105. doi: 10.1016/j.ajo.2007.09.002. Epub 2007 Nov 8.
PubMed 17996211
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Deep Lamellar Endothelial Keratoplasty as Surgical Treatment for Corneal Endothelial Decompensation
- ClinicalTrials.gov ID
- NCT00346138
- Acronym / sponsor ID
- 1000-03
- Conditions
- Fuchs Dystrophy, Corneal Edema
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 29 participants (actual)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- Jun 2005
- Primary completion
- Jun 2009 (actual)
- Study completion
- Jun 2009 (actual)
- First posted
- 29 Jun 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objectives of this study are to compare the visual and refractive outcomes of deep lamellar endothelial keratoplasty (DLEK) with penetrating keratoplasty as treatment for certain cases of corneal edema due to endothelial decompensation. Additionally, data will be collected to compare corneal shape, corneal thickness, endothelial cell density, keratocyte density, corneal sensitivity, light scatter, and subjective visual function between the two procedures.
Detailed description
This will be a randomized prospective study. We will enroll patients using the following inclusion and exclusion criteria, based upon the surgeon?s initial complete ophthalmic examination, which includes refraction, keratometry, slit lamp examination, intraocular pressure and corneal thickness measurement, and dilated fundus examination.
Inclusion criteria:
- Both males and females are eligible 2) Patient age 21 years or older 3) Corneal edema due to endothelial dysfunction 4) Aphakia, pseudophakia, or cataract requiring extraction 5) Visual acuity as measured in standardized fashion (ETDRS chart and appropriate illumination)
- Study eye; best spectacle-corrected entrance acuity 20/40 or worse
- Contralateral eye; best spectacle-corrected entrance acuity equal to or better than the study eye and 20/200 or better. Exclusion criteria:
- Central stromal corneal scars 2) Presence of a filtering bleb 3) History of Herpes simplex or Herpes zoster keratitis 4) Uncontrolled glaucoma 5) Pregnancy. Serum pregnancy testing will be performed within 7 days prior to surgery for women of child-bearing potential In the 2-year period, January 2001 to January 2003, 67 PK?s were performed at Mayo Clinic for endothelial dysfunction (e.g., Fuch?s dystrophy or pseudophakic corneal edema) in patients who met the entry criteria for this protocol. During the 2-year enrollment period of this study, we anticipate that up to 50 patients will be enrolled. Appropriate counseling will be done, including a discussion of the potential benefits and risks of the procedures. IRB-approved consent forms will be signed. Enrolled patients will return on a different day (often the day before surgery or the morning of surgery to be performed in the afternoon) for the preoperative Keratogram. Randomization and assignment of the patient to DLEK or PK will occur after the preoperative Keratogram and after the surgeon has accepted a donor cornea from the eye bank for the procedure. Keratogram The Keratogram consists of a series of tests administered both pre- and post-operatively by trained research personnel who are masked to the patients? particular randomizations. Keratograms will be performed preoperatively and at 1 month (3-6 weeks), 3 months (2-4 months), 6 months (5-7 months), and 1, 2, and 3 years (\3 months) postoperatively. The following measurement procedures, to be conducted only on the operated eye, are included in each Keratogram. The equipment to be used is included in parentheses:
- Contrast sensitivity with best refraction (Ginsburg contrast sensitivity tester) 2. Straylight meter measurement (Van den Berg straylight meter) 3. Corneal topography map (TMS-2) 4. Corneal profile (Orbscan) 5. Noncontact endothelial photography (Konan Robo) 6. Scatterometry (Mayo scatterometer) 7. Corneal esthesiometry (Belmonte esthesiometer) 8. Confocal microscopy (Tandem Scanning or Confoscan 3 confocal microscope) 9. Quality of visual function questionnaire (NEI-VFQ). This will not be done at the 1week, one month, or 3 month visit. Eligibility of Fellow Eyes Fellow eyes in bilateral cases will be eligible to enter the study 4 months or more after the first procedure if these eyes now meet the eligibility criteria (i.e., if the fellow eye now has worse vision than the operated study eye). These eyes will be randomized separately and follow the same protocol, with the exception that the patient may override the randomization if he or she prefers to have one or the other of the 2 procedures. For data analysis, fellow eyes will be considered a separate group. Adverse Occurrences For DLEK, adverse occurrences at the time of surgery (such as premature entry into the anterior chamber during recipient lamellar dissection) will require conversion to a standard PK and the patient will be exited from the study. Adverse postoperative occurrences in either surgical group (such as a dislocated disc, uncontrolled rejection, primary graft failure, infection or other adverse events) will be managed by the surgeon according to standard practices. These patients will remain in the study and will have identical follow-up. SURGICAL METHODS
- DLEK Anesthesia: Anesthesia options will include monitored, attended, local anesthesia or general orotracheal anesthesia, depending on the particular patient?s desire and comorbid conditions. For local anesthesia a standard retrobulbar and facial nerve block as done for standard PK will be utilized. Preparation of recipient:
- In the preoperative area, pilocarpine 1%, one drop to operated eye is instilled every five minutes for 3 doses in order to constrict the pupil.
- After anesthesia is attained and the eye is prepared and draped, the lid speculum and operating microscope with video recording of each case is brought into position.
- Rectus bridle sutures for positioning of the globe are placed as necessary.
- A limbal peritomy is performed and the conjunctiva is recessed from the 9:30 to 2:30 o'clock superior limbus.
- A limbal incision of the sclera, 1.0 mm peripheral to the limbus and parallel to the limbus, is made with a guarded diamond knife set to 0.35 mm depth. The length of the incision is 9.0 mm or 4.5mm, measured with calipers.
- Deep lamellar dissection of the cornea utilizing a crescent blade is performed followed by a stromal dissector spatula.
- Paracentesis and Healon injection to maintain the anterior chamber.
- Placement of intra-lamellar trephine with trephination of the recipient posterior stromal disc. If a 4.5mm incision was made, then the trephine is used to make an indentation on the corneal surface and the posterior lamellar disc is cut with scissors.
- Entry into anterior chamber with a diamond blade at 12 o'clock in the trephination.
- Excision of recipient posterior stromal disc and endothelium with corneal scissors and removal of disc from the eye.
- Caliper measurement of the diameter of the excised tissue is recorded.
- Wound closure and standard phacoemulsification and IOL implantation through a separate incision in patients requiring cataract removal.
- Healon is evacuated completely from the anterior chamber with an I/A unit. (eg: Simcoe Needle).
- The cornea is covered with a moistened gauze disc. Preparation of donor tissue
- Donor corneo-scleral tissue is removed from the storage media, endothelium is coated with healon, and the tissue is secured in the Moria artificial anterior chamber.
- A deep lamellar dissection pocket is formed in the donor with a crescent blade followed by a stromal dissector spatula.
- The donor tissue is placed (endothelial side up) onto the trephination block and the same size trephine (same size as recipient disc tissue diameter) is used to trephine the donor disc.
- The donor disc is separated from the corneo-scleral donor tissue and placed endothelial side down or folded in half (if a 4.5mm incision was made) onto a healon coated transfer spatula. Transfer of donor to recipient
- Air is injected into the anterior chamber. 2) The donor tissue disc is placed into the anterior chamber through the lamellar incision.
- The spatula is removed from the eye by sliding out from under the Healon coating.
- The disc position is finely manipulated with a needle or hook as needed, taking care to minimize endothelial touch.
- The limbal wound is sutured with interrupted 10-0 nylon sutures. 6) The anterior chamber air bubble is replaced 50% with balanced salt solution. 7) A Seidel test is performed. If positive, additional limbal sutures are placed.
- The conjunctiva is closed with cautery or sutures. 9) Subconjunctival dexamethasone, 2 mg or Solu-Medrol, 30 mg and cefazolin, 25 mg or gentamicin, 20 mg, are injected in the inferior fornix. The eye is bandaged with a gauze patch and a Fox shield.
- The patient is instructed to spend the next two postoperative hours in a supine position.
- Routine postoperative orders for corneal transplantation are given upon discharge from the hospital that day.
- PK The surgical method for patients randomized to penetrating keratoplasty will be the standard procedure currently practiced by the participating surgeons. POSTOPERATIVE CARE The patient will be seen the day after the surgery. Postoperative medications will include topical antibiotic of the surgeon?s choice, twice daily for one to two weeks and prednisolone acetate 1%, four times daily. The steroid drop will be tapered by one drop daily each month. Alterations to the steroid taper and other medical treatment will be made based upon individual patient conditions and response. Patient activity restrictions and eye protection measures will follow the usual PK recommendations by the individual surgeon. All patients will be seen at the following intervals: preoperatively and at 1 week (5-14 days), 1 month (3-6 weeks), 3 months (4-6 months), 6 months (5-7 months), and 1, 2, and 3 years (\3 months) postoperatively. Keratograms will be performed at each visit, except one day and one week postoperatively. Confocal microscopy will be done as part of each keratogram and also at the one week postoperative visit. Additional clinic visits may be requested by the surgeon as needed for proper medical management. Corneal suture removal in penetrating grafts or limbal suture removal in DLEK will be dictated by patient healing and at the surgeon?s discretion. DATA COLLECTION AND STATISTICAL ANALYSIS Data collection will be performed with the instruments and schedule delineated above in the Methods section. The following outcome measures will be calculated from the data. These will be compared between the 2 groups (DLEK and PK) at each postoperative time by using t-tests or rank sum tests with Bonferroni corrections. Primary Outcome Measures
- Visual acuity with best refractive correction
- Refractive astigmatism
- Keratometric astigmatism
- Topographic astigmatism ("Simulated Keratometry" function of the TMS-1 mapping) Secondary Outcome Measures <!-- -->
- Corneal backscattered light
- Ocular forward-scattered light
- Contrast sensitivity
- Posterior corneal curvature
- Corneal sensitivity
- Corneal subbasal nerve density
- Keratocyte density
- Endothelial cell density
- Quality of visual function (NEI-VFQ) Statistical Power We have recently published variance data on keratometric astigmatism and endothelial cell density after PK. The keratometric astigmatism17 after removal of all sutures was 4.6 \ 2.7 D (mean\SD) and the endothelial cell density18 2 months postoperatively was 2606 \ 446 cells/mm2. To detect (\=0.05) a difference of 2.5 D in keratometric astigmatism with 80% certainty (\=0.2) would require 20 subjects in each group, and to detect a difference of 400 cells/mm2 in endothelial cell density would require 20 subjects in each group. We expect to have 25 patients in each group, giving the study adequate power. For an additional use of the data, primary outcome data on the patients randomized to DLEK from our center will be pooled with data from other participating centers in the Endothelial Keratoplasty Group organized by Mark Terry, M.D., Portland, OR, who will coordinate data collection and statistical analysis. Pooled data will be used to calculate mean postoperative visual acuity, refractive outcomes and frequency of favorable outcome. These data will be compared with published data on PK.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Corneal transplantation | Procedure or surgery | – |
Primary outcome
Visual acuity.
5 secondary outcomes
Astigmatism
contrast sensitivity
corneal haze
endothelial cell density
corneal thickness
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2010.
- Derived from this study: PubMed 25015214Trousdale ER, Hodge DO, Baratz KH, Maguire LJ, Bourne WM, Patel SV. Vision-related quality of life before and after keratoplasty for Fuchs' endothelial dystrophy. Ophthalmology. 2014 Nov;121(11):2147-52. doi: 10.1016/j.ophtha.2014.04.046. Epub 2014 Jul 9.
- Derived from this study: PubMed 22357383Ahuja Y, Baratz KH, McLaren JW, Bourne WM, Patel SV. Decreased corneal sensitivity and abnormal corneal nerves in Fuchs endothelial dystrophy. Cornea. 2012 Nov;31(11):1257-63. doi: 10.1097/ICO.0b013e31823f7888.
- Derived from this study: PubMed 19298950McLaren JW, Patel SV, Bourne WM, Baratz KH. Corneal wavefront errors 24 months after deep lamellar endothelial keratoplasty and penetrating keratoplasty. Am J Ophthalmol. 2009 Jun;147(6):959-65, 965.e1-2. doi: 10.1016/j.ajo.2008.12.039. Epub 2009 Mar 19.
- Derived from this study: PubMed 17996211Patel SV, McLaren JW, Hodge DO, Baratz KH. Scattered light and visual function in a randomized trial of deep lamellar endothelial keratoplasty and penetrating keratoplasty. Am J Ophthalmol. 2008 Jan;145(1):97-105. doi: 10.1016/j.ajo.2007.09.002. Epub 2007 Nov 8.
Related trials for Fuchs Dystrophy
RecruitingPhase 2
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
Corneal Edema, Fuchs
RecruitingObservational study
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Keratoconus, Ectasia
RecruitingPhase 2
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
Fuchs Endothelial Corneal Dystrophy, Fuchs
Active, not recruiting
The Belgian Endothelial Surgical Transplant of the Cornea
Corneal Edema, Corneal Endothelial Disorder
Enrolling by invitationObservational study
The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy
Fuchs Endothelial Corneal Dystrophy, Cataract
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Corneal transplantation in people with Fuchs Dystrophy and Corneal Edema, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jan 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual acuity.. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00346138, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2010.